<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1004257224
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1998
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BACTRIM FORTE TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SULFAMETHOXAZOLE,TRIMETHOPRIM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        800,160
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23.3
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01EE01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
            <div class="p-20 text-center font-20">
                <div class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</div>
            </div>
    </div>
    <div id="A-div" class="box-data">
            <div class="p-20 text-center font-20">
                <span class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</span>
            </div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -Bactrim Forte 800mg+160mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active substances
Trimethoprim (TM) and sulfamethoxazole (SMZ). The combination of the two active substances
TM and SMZ has become established under the name Bactrim.
Excepients
For a full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bactrim forte, Tablets, 160 mg TM and 800 mg SMZ.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Owing to the sometimes serious side effects of Bactrim and the emergence of resistance, a riskbenefit<br />assessment versus other active substances that may also be suitable for these indications<br />should always be carried out prior to use of Bactrim.<br />Infections caused by co-trimoxazole -susceptible organisms, such as:<br />Infections of the upper and lower respiratory tract and ear: acute exacerbations of chronic<br />bronchitis, bronchiectasis, pneumonia (including Pneumocystis jirovecii (formerly carinii)<br />pneumonia), sinusitis, otitis media.<br />Infections of the urogenital system: acute and chronic cystitis, pyelonephritis, urethritis, prostatitis.<br />Infections of the gastrointestinal tract: travellers&#39; diarrhoea, chronic typhoid fever carriers, cholera<br />(as an adjunct to fluid and electrolyte intake).<br />Cotrimoxazole should be used for the following infections only if other currently recommended<br />antibiotics cannot be administered:<br />Typhoid fever, paratyphoid A and B, Salmonella enteritis with septic progression in<br />immunocompromised patients.</p><p>Note:<br />Gastroenteritis caused by Salmonella enteritidis should generally not be treated with Bactrim, as<br />the course of the disease is not affected and excretion is even prolonged (for exception, see above).<br />Other infections, if caused by susceptible organisms: acute brucellosis, nocardiosis, mycetoma<br />(unless caused by true fungi), South American blastomycosis (Paracoccidioides brasiliensis).<br />In osteomyelitis as a last-line medicinal product for (i.e. where there is a contraindication to<br />vancomycin, for example), for multi-resistant organisms and where susceptibility to Bactrim has<br />been demonstrated.<br />Official recommendations on the appropriate use of antibiotics should be followed, in particular<br />recommendations on use to prevent the increase in antibiotic resistance.<br />Bactrim should be used only to treat or prevent infections that are proven or strongly suspected to<br />be caused by susceptible bacteria or other susceptible micro-organisms. In the absence of relevant<br />data, local epidemiology and susceptibility&nbsp;&nbsp;patterns may contribute to empirical selection of the<br />appropriate antibiotic therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Standard dosage<br />Bactrim is administered at 12-hourly intervals. As a rule, adults and children aged 12 and over<br />receive the forte tablets, and children under 12 years of age, receive the oral suspension.<br />The usual dosage for adults and children aged 12 and over:<br />TABLE 1</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="width:198px">&nbsp;</td><td style="width:122px">Forte tablets</td><td style="width:178px">&nbsp;</td></tr><tr><td style="width:198px">&nbsp;</td><td style="width:122px">morning</td><td style="width:178px">evening</td></tr><tr><td style="width:198px">Standard dosage</td><td style="width:122px">1&nbsp;</td><td style="width:178px">1</td></tr><tr><td style="width:198px">Minimum dosage and dosage for<br />long-term treatment<br />(more than 14 days)</td><td style="width:122px">&frac12;</td><td style="width:178px">&frac12;</td></tr><tr><td style="width:198px">High dosage<br />(for severe cases)</td><td style="width:122px">1 &frac12;</td><td style="width:178px">1 &frac12;</td></tr></tbody></table><p>&nbsp;</p><p>Duration of treatment<br />For acute infections, treatment with the oral form should last at least 5 days.</p><p>Special dosage instructions<br />Acute uncomplicated urinary tract infections<br />To treat acute uncomplicated urinary tract infections in women, a single administration of 2&ndash;3 forte<br />tablets is recommended. These are best taken after the evening meal or at bedtime.<br />Patients with Pneumocystis jirovecii pneumonia<br />The recommended dosage is up to 20 mg TM per kg and 100 mg SMZ per kg per 24 hours, given<br />orally in equal divided doses every six hours for 14 days.<br />Table 2 below gives a general guide to the upper dosage limit based on body weight for patients<br />with Pneumocystis jirovecii pneumonia:<br />TABLE 2</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:366px"><tbody><tr><td style="width:210px">Bodyweight<br />[kg]</td><td style="width:152px"><p>Dose &ndash; every 6 hours</p><p>Forte tablets</p></td></tr><tr><td style="width:210px">8<br />16<br />24<br />32<br />40<br />48<br />64<br />80</td><td style="width:152px">-<br />-<br />-<br />1<br />-<br />1&frac12;<br />2<br />2&frac12;</td></tr></tbody></table><p>Pneumocystis jirovecii pneumonia prophylaxis<br />The recommended dosage for prophylaxis of Pneumocystis jirovecii pneumonia in adolescents and<br />adults is 1 forte tablet 3 times/week.<br />TABLE 3</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="width:240px">Body surface area</td><td style="width:258px">Dose every 12 hours</td></tr><tr><td style="width:240px">(m2)</td><td style="width:258px">Tablets</td></tr><tr><td style="width:240px">0.26</td><td style="width:258px">--</td></tr><tr><td style="width:240px">0.53</td><td style="width:258px">1/2</td></tr><tr><td style="width:240px">1.06</td><td style="width:258px">1</td></tr></tbody></table><p>&nbsp;</p><p>Patients with nocardiosis<br />The recommended dosage for adults with nocardiosis is 3 - 4 forte tablets daily for at least<br />3 months. This dosage recommendation is to be adjusted to the patient&#39;s age, weight, renal function<br />and disease severity. Long-term treatment over the course of 18 months has been reported.</p><p>Patients with renal dysfunction<br />Dosage recommendation for patients with impaired renal function:</p><p>TABLE 4</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="width:251px">Creatinine clearance</td><td style="width:247px">Recommended dosage regimen</td></tr><tr><td style="width:251px">&gt; 30 ml/min</td><td style="width:247px">Standard dosage</td></tr><tr><td style="width:251px">15&ndash;30 ml/min</td><td style="width:247px">Half the standard dosage</td></tr><tr><td style="width:251px">&lt; 15 ml/min</td><td style="width:247px">Should not be used (see<br />&quot;Contraindications&quot;)</td></tr></tbody></table><p>&nbsp;</p><p>Dialysis patients<br />Patients on haemodialysis should initially receive a standard starting dose of TM-SMZ, followed<br />by an additional half dose after each haemodialysis session.<br />Serum concentrations of the medicinal product should be monitored in order to adjust the dosage.<br />Patients on haemodialysis should be closely monitored for signs and symptoms of toxicity.<br />Peritoneal dialysis results in only minimal clearance of administered TM and SMZ. The use of<br />TM-SMZ in patients receiving peritoneal dialysis is not recommended.<br />Method of administration<br />Bactrim is best taken after meals with plenty of liquid.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to the active substances, to sulphonamides or trimethoprim or any of the
excipients listed under Composition.
- Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis and drug rash
with eosinophilia and systemic symptoms (including a history thereof).
- Congenital glucose-6-phosphate dehydrogenase deficiency in red blood cells, haemoglobin
abnormalities such as Hb Köln and Hb Zurich.
- Acute porphyria.
- Neonates with hyperbilirubinaemia or glucose-6-phosphate dehydrogenase deficiency in red
blood cells.
- Marked damage to the liver parenchyma (e.g. acute hepatitis).
- Severe renal insufficiency (creatinine clearance < 15 ml/min).
- Pathological blood count changes such as megaloblastic anaemia due to folic acid deficiency,
thrombocytopenia, granulocytopenia.
- Use in premature babies or neonates during the first six weeks of life, as this can lead to an
increased risk of kernicterus.
- Use during the final trimester of pregnancy (see section 4.6 "Fertility, pregnancy and
lactation").
- Combination with dofetilide (see section 4.5 "Interactions with other medicinal products and
other forms of interaction")
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment is to be discontinued without delay at the first signs of rash or other severe side effects<br />(such as haematological side effects, for example).<br />Flu-like symptoms, sore throat or fever may be symptoms of blood count changes. If these<br />symptoms occur, blood counts must be carried out immediately.<br />Bactrim should be administered with caution to patients with a history of allergy or bronchial<br />asthma.<br />Very rare, severe cases of respiratory toxicity, sometimes progressing to Acute Respiratory Distress<br />Syndrome (ARDS), have been reported during Bactrim treatment. The onset of pulmonary signs<br />such as cough, fever, and dyspnoea in association with radiological signs of pulmonary infiltrates,<br />and deterioration in pulmonary function may be preliminary signs of ARDS. In such circumstances,<br />Bactrim should be discontinued and appropriate treatment given.<br />In connection with adverse effects such as blood dyscrasias (aplasia, agranulocytosis,<br />thrombopenia), severe cutaneous adverse reactions (SCARs), for example, severe erythema<br />multiforme (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell&#39;s syndrome), drug rash<br />with eosinophilia and systemic symptoms (DRESS), acute generalised exanthematous pustulosis<br />(AGEP) as well as fulminant hepatic necrosis. Cases with a fatal outcome have been reported -<br />albeit rarely. Patients should be informed of the signs and symptoms of these serious side effects<br />and be closely monitored for the occurrence of skin reactions.</p><p>The risk of developing SJS, TEN or DRESS is highest in the first weeks of treatment. If signs or<br />symptoms of SJS, TEN or DRESS occur (e.g. a progressive skin rash, often with blistering or<br />accompanying mucosal lesions), treatment with Bactrim must be discontinued.<br />The course of SJS, TEN and DRESS is largely determined by early diagnosis and immediate<br />discontinuation of all suspect medicinal products, i.e. early discontinuation improves the prognosis.<br />After the occurrence of SJS, TEN or DRESS associated with the use of Bactrim, the patient must<br />never again be treated with Bactrim.<br />Cases of haemophagocytic lymphohistiocytosis (HLH) have been reported very rarely in patients<br />treated with Bactrim. HLH is a life-threatening syndrome of pathologic immune activation<br />characterised by clinical signs and symptoms of excessive systemic inflammation (e.g. fever,<br />hepatosplenomegaly, hypertriglyceridaemia, hypofibrinogenaemia, high serum ferritin, cytopenias<br />and haemophagocytosis). Patients who develop early manifestations of pathologic immune<br />activation should be evaluated immediately. If a diagnosis of HLH is established, Bactrim<br />treatment should be discontinued.<br />Haematological events are more common in:<br />- the elderly, and<br />- people with existing folic acid deficiency (advanced age, pregnancy (see section 4.3<br />&quot;Contraindications&quot;), alcoholism, chronic hepatic insufficiency, malnutrition, chronic<br />malabsorption). These haematological changes are reversible after treatment with folic acid.<br />It is recommended that treatment with the trimethoprim-sulfamethoxazole combination not exceed<br />ten days in these patients.<br />Periodic haematological monitoring is necessary in the following cases:<br />- prolonged or repeated treatments,<br />- people over 65 years of age, and<br />- people with folic acid deficiency.<br />Use of the trimethoprim-sulfamethoxazole combination is not recommended in macrocytic<br />anaemia (see section 4.3 &quot;Contraindications&quot;).</p><p>&nbsp;</p><p>Patients to whom Bactrim must be administered for a prolonged period of time should have their<br />blood count checked regularly. Bactrim must be discontinued in the event of a significant reduction<br />in a cellular element compared with the norm.<br />Bactrim is not recommended during pregnancy or in women who are planning to have a baby<br />unless the benefit to the patient clearly outweighs the risk, as TM and SMZ cross the placental<br />barrier, affect foetal folic acid metabolism and may therefore pose a potential risk to the foetus,<br />and clinical studies have shown an increased risk of spontaneous abortion.<br />Women of childbearing potential who are planning to have a baby should take a pregnancy test<br />before starting treatment with Bactrim, and pregnancy should be ruled out.<br />Renal effects<br />Sulphonamides, including Bactrim, may cause increased diuresis, especially in patients with<br />cardiac oedema.<br />Close monitoring of serum potassium and renal function is required in patients who are receiving<br />high doses of Bactrim, as used in patients with Pneumocystis jirovecii pneumonia, or in patients<br />who are receiving standard doses of Bactrim and have underlying disorders of potassium<br />metabolism or renal insufficiency, or who are receiving medicinal products that cause<br />hyperkalaemia (see section 4.5 &quot;Interactions with other medicinal products and other forms of<br />interaction&quot;).<br />During treatment with Bactrim, the patient should ensure adequate fluid intake in order to prevent<br />crystalluria.<br />Specific patient groups<br />In the elderly, in patients with additional complications, such as impaired renal and/or hepatic<br />function, as well as when other medicinal products are administered concomitantly, there is an<br />increased risk of serious side effects, depending on the dose and treatment duration.<br />In the event of impaired renal function, the dosage should be adjusted in accordance with the<br />specific dosing instructions. Patients with severe renal impairment (i.e. with a creatinine clearance<br />of 15&ndash;30 ml/min) who are receiving TM-SMZ should be closely monitored for toxicity symptoms<br />and signs such as nausea, vomiting and hyperkalaemia.<br />Patients with severe blood dyscrasias are to be treated with Bactrim only in exceptional cases.</p><p>&nbsp;</p><p>Occasionally, the preparation has been administered to leukaemia patients who were under the<br />influence of cytostatic drugs; they displayed no additional adverse effect on the bone marrow or<br />peripheral blood count.<br />Patients with G6PD deficiency and patients with certain haemoglobin disorders (Hb Zurich, Hb<br />K&ouml;ln) may develop cyanosis due to sulfhaemoglobinaemia or methaemoglobinaemia. Glucose-6-<br />phosphate dehydrogenase deficiency can induce haemolysis in susceptible patients regardless of<br />the dose (see section 4.3 &quot;Contraindications&quot;).<br />To minimise the risk of adverse effects, treatment with Bactrim should be as short as possible,<br />especially in elderly patients.<br />Severe and persistent diarrhoea during or after therapy may be an indication of pseudomembranous<br />colitis, which must be treated immediately. In such cases, Bactrim should be discontinued and an<br />appropriate diagnostic work-up and therapy should be initiated (e.g. oral vancomycin, 4 x 250 mg<br />daily). Antiperistaltic agents are contraindicated.<br />If administered for a prolonged period of time, urine and renal function should be monitored<br />(especially in patients with kidney injury).<br />Given that Bactrim, like other antibiotics, can reduce the effectiveness of oral contraceptives,<br />female patients should be advised to take additional contraceptive measures during treatment with<br />Bactrim.<br />Prolonged therapy with Bactrim may lead to the proliferation of non-susceptible bacteria and fungi.<br />In the event of a superinfection, suitable therapy should be initiated immediately.<br />Caution is advised in patients with porphyria or thyroid dysfunction.<br />In elderly patients and in patients with renal insufficiency, haematological changes suggestive of<br />folic acid deficiency may occur; however, these can be reversed by means of folic acid treatment.<br />Caution is advised in patients who have an additional risk factor for folic acid deficiency, e.g.<br />phenytoin therapy with other folic acid antagonists, malnutrition.<br />Simultaneous administration of Bactrim and phenytoin is not recommended (see section 4.5<br />&quot;Interactions with other medicinal products and other forms of interaction&quot;).<br />Cases of pancytopenia have been reported in patients who have received the combination of<br />trimethoprim and methotrexate. Simultaneous administration of Bactrim and methotrexate is not</p><p>recommended (see section 4.5 &quot;Interactions with other medicinal products and other forms of<br />interaction&quot;).<br />Patients who are &quot;slow acetylators&quot; may have an increased risk of idiosyncratic reactions to<br />sulphonamides.<br />Bactrim forte and Bactrim Tablets (export)<br />This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially<br />&quot;sodium-free&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetic interactions<br />Trimethoprim is an inhibitor of organic cation transporter 2 (OCT2) and a weak inhibitor of<br />CYP2C8. Sulfamethoxazole is a weak inhibitor of CYP2C9.<br />Raised blood digoxin levels may occur with concomitant Bactrim therapy, especially in elderly<br />patients.<br />Bactrim, given at standard doses, prolonged the phenytoin half-life by 39% whereas it decreased<br />phenytoin clearance by 27%. Simultaneous administration of Bactrim and phenytoin is not<br />recommended. If concomitant administration is essential, patients receiving phenytoin should be<br />monitored for signs of phenytoin toxicity, and serum phenytoin concentrations should be monitored.<br />Patients receiving sulfonylurea derivatives (such as glibenclamide, gliclazide, glipizide,<br />chlorpropamide and tolbutamide) or repaglinide, rosiglitazone or pioglitazone should be monitored<br />regularly for hypoglycaemia.<br />Sulphonamides, including sulfamethoxazole, may displace methotrexate from plasma protein<br />binding sites and interfere with its renal transport, thereby increasing the concentration of free<br />methotrexate and enhancing its action and haematological side effects. Simultaneous<br />administration of Bactrim and methotrexate is not recommended.<br />Bactrim may affect the required dose of oral antidiabetic agents.<br />Bactrim, like other antibiotics, may reduce the effectiveness of oral contraceptives. Female patients<br />should therefore be advised to take additional contraceptive measures during treatment with<br />Bactrim</p><p>Observed interactions<br />An increased incidence of thrombocytopenia with purpura has been observed in elderly patients<br />concomitantly receiving certain diuretics (primarily thiazides). The platelet count should therefore<br />be monitored regularly during use of diuretics.<br />On co-administration with Bactrim, there may be an increase in systemic exposure to active<br />substances that are primarily metabolised via CYP2C9, such as coumarins (warfarin,<br />acenocoumarol, phenprocoumon), phenytoin and sulphonylurea derivatives (glibenclamide,<br />gliclazide, glipizide, chlorpropamide and tolbutamide).<br />Coagulation should be monitored in patients who are being treated with coumarins.<br />Reversible impairment of renal function has been observed in patients treated with Bactrim and<br />ciclosporin following kidney transplantation.<br />Cases of pancytopenia have been reported in patients who have received the combination of<br />trimethoprim and methotrexate (see &quot;Warnings and precautions&quot;). Trimethoprim has a low affinity<br />for human dihydrofolate reductase, but it may increase the side effects of methotrexate, especially<br />in the presence of risk factors such as advanced age, hypoalbuminaemia, impaired renal function<br />and reduced bone marrow reserve, as well as in patients receiving high-dose methotrexate. At-risk<br />patients should be treated with folic acid or calcium folinate in order to counteract the effects of<br />methotrexate on haematopoiesis (rescue).<br />Occasional reports suggest that patients taking pyrimethamine for malaria prophylaxis in doses<br />exceeding 25 mg pyrimethamine weekly may develop megaloblastic anaemia when Bactrim is coadministered.<br />Due to the potassium-sparing effect of Bactrim, caution is advised when it is co-administered with<br />other substances that increase serum potassium levels, such as angiotensin-converting enzyme<br />inhibitors, angiotensin receptor blockers, potassium-sparing diuretics and prednisolone.<br />Frequent serum potassium monitoring is advised, especially in patients with underlying potassium<br />disorders, renal insufficiency or those receiving high doses of Bactrim.<br />When used concomitantly with Bactrim, there may be an increase in systemic exposure to active<br />substances transported by OCT2, such as dofetilide, amantadine, memantine and lamivudine.<br />Bactrim must not be used in combination with dofetilide (see section 4.3 &quot;Contraindications&quot;).<br />There is evidence that TM inhibits the excretion of dofetilide via the kidneys. Simultaneous&nbsp;administration of trimethoprim 160 mg in combination with sulfamethoxazole 800 mg twice daily<br />and dofetilide 500 &mu;g twice daily for 4 days resulted in a 103% increase in the area under the<br />concentration-time curve (AUC) of dofetilide and a 93% increase in peak plasma concentration<br />(Cmax). Dofetilide can cause prolongation of the QT interval with serious ventricular arrhythmia,<br />including torsade de pointes; these are directly dependent on the plasma concentration of dofetilide.<br />Patients treated with amantadine or memantine may have an increased risk of neurological adverse<br />events such as delirium or myoclonus. Toxic delirium after simultaneous intake of Bactrim and<br />amantadine has been reported.<br />When used concomitantly with Bactrim, there may be an increase in systemic exposure to active<br />substances that are primarily metabolised via CYP2C8, such as paclitaxel, amiodarone, dapsone,<br />repaglinide, rosiglitazone and pioglitazone.<br />Paclitaxel and amiodarone have a narrow therapeutic margin; simultaneous use with TM-SMZ is<br />therefore not recommended.<br />Both dapsone and Bactrim can cause methaemoglobinuria. Patients receiving dapsone in<br />combination with Bactrim should be monitored for methaemoglobinuria. Where possible,<br />alternative therapies should be considered.<br />Pharmacodynamic interactions<br />The incidence rate and severity of myelotoxic and nephrotoxic adverse reactions may be increased<br />when TM-SMZ is administered concomitantly with other medicinal products known to have<br />myelosuppressive or nephrotoxic properties, such as nucleoside analogues, tacrolimus,<br />azathioprine or mercaptopurine. Patients receiving TM-SMZ together with such medicinal<br />products should be monitored for haematological and/or renal toxicity. Alternatives to Bactrim<br />should be considered in patients receiving azathioprine or mercaptopurine.<br />Simultaneous use with clozapine, an active substance with considerable potential to induce<br />agranulocytosis, should be avoided.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Bactrim is not recommended during pregnancy or in women who are planning to have a baby<br />unless the benefit to the patient clearly outweighs the risk, as TM and SMZ cross the placental&nbsp;barrier, affect foetal folic acid metabolism and may therefore pose a potential risk to the foetus,<br />and clinical studies have shown an increased risk of spontaneous abortion.<br />Women of childbearing potential who are planning to have a baby should take a pregnancy test<br />before starting treatment with Bactrim, and pregnancy should be ruled out.<br />A congenital G6PD deficiency may result in neonatal haemolysis.<br />First trimester<br />Two large-scale observational studies showed that women treated with TM alone and in<br />combination with SMZ in the first trimester had a 2- to 3.5-fold increased risk of spontaneous<br />abortion compared with no exposure to antibiotics or exposure to penicillins.<br />The risk of congenital malformations in women undergoing Bactrim therapy during early pregnancy<br />could not be conclusively demonstrated. At very high doses of Bactrim, animal studies produced<br />malformations typical of folic acid antagonism.<br />Studies in animals have shown that very high doses of Bactrim cause foetal malformations typical<br />of folic acid antagonism (see &quot;Preclinical data&quot;). However, two studies suggest that, when folic acid<br />antagonists including TM-SMZ are given to a woman during the three months after her last<br />menstrual period, there is a possibility of specific neural tube and cardiac defects. The cause is<br />suspected to be interference with folates. These results have yet to be confirmed and are not, in<br />themselves, sufficient to advise a termination. If the trimethoprim-sulfamethoxazole combination<br />is nevertheless used at the beginning of pregnancy, dietary supplementation with folic acid for the<br />duration of treatment can be suggested but its effectiveness in preventing these abnormalities has<br />not yet been demonstrated. It is recommended that women who are pregnant or planning to have a<br />baby and cannot be given an alternative to Bactrim treatment receive an additional 5 mg of folic<br />acid per day during necessary Bactrim treatment.<br />Third trimester<br />Bactrim is contraindicated in the last trimester as it could lead to an increased risk of neonatal<br />kernicterus (see section 4.3 &ldquo;Contraindications&rdquo; and section 5.2.2 Distribution&quot;).<br />Lactation<br />TM and SMZ are excreted in human milk. Although the amount ingested by the infant is extremely<br />small, the benefit to the mother should still be weighed carefully against the risk to the infant&nbsp;(kernicterus, hypersensitivity) (see section 4.3 &ldquo;Contraindications&rdquo; and section 5.2.2<br />Distribution&quot;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bactrim has no influence on the ability to drive and use machines. However, adverse reactions that<br />interfere with these abilities, sometimes severely, are possible (see &quot;Undesirable effects&quot;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The main adverse effects include skin reactions and mild gastrointestinal symptoms, which have<br />occurred in about 5% of treatment periods.<br />The following adverse effects have been reported (by frequency and by MedDRA system organ<br />class):<br />&quot;Very common&quot; (&ge; 1/10), &quot;common&quot; (&ge; 1/100, &lt; 1/10), &quot;uncommon&quot; (&ge; 1/1000, &lt; 1/100), &quot;rare&quot;<br />(&ge; 1/10,000, &lt; 1/1000), &quot;very rare&quot; (&lt; 1/10,000), &quot;not known&quot; (cannot be estimated from the<br />available data).<br />Infections and infestations<br />Uncommon: fungal infections such as candidiasis.<br />Blood and lymphatic system disorders<br />Rare: leukopenia, granulocytopenia, thrombocytopenia, anaemia (megaloblastic,<br />immunohaemolytic, aplastic anaemia).<br />Very rare: agranulocytosis, methaemoglobinaemia, pancytopenia.<br />Most of the haematological changes observed have been mild, asymptomatic and reversible upon<br />discontinuation of the medicinal product.<br />Congenital disorders and pregnancy, puerperium and perinatal conditions<br />Not known: spontaneous abortion<br />Immune system disorders<br />Very rare: allergic reactions such as fever, angioedema, anaphylactoid reactions and serum<br />sickness.</p><p>Metabolism and nutrition disorders<br />Rare: hypoglycaemia in non-diabetic patients, generally occurring in the first few days of<br />treatment. Patients with impaired renal function, liver disease or malnutrition and patients receiving<br />high-dose TM-SMZ are particularly at risk.<br />Psychiatric disorders<br />Rare: hallucinations, delirium and psychosis, especially in elderly patients.<br />Nervous system disorders<br />Uncommon: convulsions.<br />Rare: neuropathy (including peripheral neuritis and paraesthesia).<br />Very rare: aseptic meningitis or meningitis-like symptoms, ataxia.<br />Not known: cerebral vasculitis.<br />Eye disorders<br />Very rare: uveitis.<br />Not known: retinal vasculitis.<br />Ear and labyrinth disorders<br />Very rare: dizziness, tinnitus.<br />Cardiac disorders<br />Very rare: allergic myocarditis, QT interval prolongation, torsade de pointes.<br />Vascular disorders<br />Very rare: purpura, Henoch-Sch&ouml;nlein purpura.<br />Not known: vasculitis, necrotising vasculitis, granulomatosis with polyangiitis, polyarteritis<br />nodosa.<br />Respiratory, thoracic and mediastinal disorders<br />Very rare: allergic pulmonary reactions (lung infiltration, interstitial and eosinophilic pneumonia,<br />respiratory insufficiency). These reactions are more common in AIDS patients.<br />Lung infiltration, which has been reported in connection with eosinophilic or allergic alveolitis,<br />may manifest as symptoms such as cough or dyspnoea.<br />Not known: pulmonary vasculitis.</p><p>Gastrointestinal disorders<br />Common: nausea, vomiting.<br />Uncommon: diarrhoea, pseudomembranous enterocolitis.<br />Rare: stomatitis, glossitis.<br />Not known: acute pancreatitis.<br />Hepatobiliary disorders<br />Common: increased transaminase levels.<br />Uncommon: increased bilirubin, hepatitis.<br />Rare: cholestasis.<br />Very rare: liver necrosis.<br />Not known: vanishing bile duct syndrome.<br />Skin and subcutaneous tissue disorders<br />Common: fixed drug eruption, exfoliative dermatitis, maculopapular rash, morbilliform rash,<br />erythema, pruritus, rashes.<br />These side effects are generally mild and rapidly reversible upon discontinuation of the preparation.<br />Uncommon: urticaria.<br />Not known: dermatosis, acute febrile neutrophilic dermatosis (Sweet&#39;s syndrome)<br />In common with many other medicinal products containing sulphonamides:<br />Very rare: erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell&#39;s<br />syndrome), drug reaction with eosinophilia and systemic symptoms (DRESS), photosensitivity,<br />acute generalised exanthematous pustulosis.<br />Musculoskeletal and connective tissue disorders<br />Very rare: rhabdomyolysis.<br />Not known: arthralgia, myalgia.<br />Renal and urinary disorders<br />Common: elevated levels of blood urea nitrogen (BUN), elevated serum creatinine levels.</p><p>Uncommon: kidney dysfunction (to the point of kidney failure).<br />Rare: crystalluria.<br />Very rare: interstitial nephritis, increased diuresis, especially in patients with cardiac oedema.<br />Investigations<br />Very common: hyperkalaemia, hyponatraemia.<br />High-dose TM, as used in patients with Pneumocystis jirovecii pneumonia, induces a progressive<br />but reversible increase in the serum potassium concentration in a significant proportion of patients.<br />TM can cause hyperkalaemia very commonly (in 60% or more of patients), even at the<br />recommended doses, in patients who have potassium metabolism disorders or renal insufficiency<br />or who are being administered medication that causes hyperkalaemia.<br />Undesirable effects in HIV patients<br />HIV patients with frequent comorbidities and their treatments usually receive prolonged<br />prophylaxis or therapy of Pneumocystis jirovecii pneumonia with high doses of Bactrim. In these<br />patients, the spectrum of side effects &ndash; with the exception of a few additional side effects &ndash; is<br />approximately the same as in the general population without HIV infection. However, certain side<br />effects are more common (about 65%) and often more severe, with the result that treatment with<br />Bactrim has to be interrupted or discontinued in 20&ndash;25% of patients.<br />The following side effects, in particular, have been observed increasingly or additionally:<br />Blood and lymphatic system disorders<br />Very common: primarily neutropenia, but also anaemia, leukopenia, granulocytopenia and<br />thrombocytopenia.<br />Metabolism and nutrition disorders<br />Uncommon: hypoglycaemia.<br />Psychiatric disorders<br />Very rare: acute psychosis.</p><p>Nervous system disorders<br />Very rare: parkinsonian resting tremor, sometimes in combination with apathy, foot clonus and<br />splayed gait.<br />Gastrointestinal disorders<br />Very common: loss of appetite, nausea, vomiting, diarrhoea.<br />Very rare: pancreatitis.<br />Hepatobiliary disorders<br />Very common: increased transaminases, cholestatic jaundice.<br />Very rare: sometimes severe hepatitis.<br />Skin and subcutaneous tissue disorders<br />Very common: maculopapular rash that causes itching over time and is rapidly reversible upon<br />discontinuation of the preparation, usually with pruritus.<br />Rare: photosensitivity.<br />Musculoskeletal and connective tissue disorders<br />Very rare: arthralgia, myalgia.<br />Renal and urinary disorders<br />Uncommon: azotaemia, crystalluria.<br />General disorders and administration site conditions<br />Very common: fever, usually associated with skin rashes.<br />Investigations<br />Very common: hyperkalaemia.<br />High-dose TM, as used in patients with Pneumocystis jirovecii pneumonia, induces a progressive<br />but reversible increase in the serum potassium concentration in a significant proportion of patients.<br />TM can cause hyperkalaemia very commonly (in 60% or more of patients), even at the&nbsp;recommended doses, in patients who have potassium metabolism disorders or renal insufficiency<br />or who are being administered medication that causes hyperkalaemia.<br />Uncommon: hyponatraemia.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is very<br />important. It allows continued monitoring of the benefit/risk balance of the medicinal product.<br />Healthcare professionals are asked to report any suspected adverse reactions online via the Elvis<br />portal (Electronic Vigilance System). You can obtain information about this at<br />www.swissmedic.ch.</p><p>&nbsp;</p><p>To report any side effect(s):<br />For Saudi Arabia:<br />&bull; The National Pharmacovigilance and Drug Safety Centre (NPC)<br />&bull; Fax: +966-11-205-7662<br />&bull; Call NPC at +966-11-2038222, Exts: 2317-2356-2340.<br />&bull; Reporting hotline: 19999.<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Signs and symptoms<br />The following symptoms are possible in the event of an acute overdose: nausea, vomiting,<br />headache, dizziness, drowsiness, mental and visual disturbances; in severe cases, crystalluria,<br />haematuria and anuria.<br />Chronic overdose: bone marrow depression presenting as thrombocytopenia, leukopenia or other<br />blood dyscrasias as a result of folic acid deficiency.</p><p>Treatment<br />Depending on the symptom, the following measures should be considered: prevention of further<br />absorption, acceleration of renal excretion by forced diuresis (alkalinisation of the urine accelerates<br />SMZ excretion), haemodialysis (note: peritoneal dialysis is not effective), blood count and<br />electrolyte monitoring. These complications should be treated specifically in cases of marked blood<br />dyscrasias or jaundice. Calcium folinate, 3&ndash;6 mg IM for 5&ndash;7 days, maybe administered as an<br />antidote to the effect of TM on haematopoiesis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC code: J01EE01<br />Mechanism of action<br />The two active substances in Bactrim elicit synergistic activity based on the blockade of two<br />enzymes that catalyse successive reactions in the biosynthesis of folinic acid in microoganisms.<br />Due to this mechanism of action, the bactericidal effect of Bactrim in vitro usually occurs at<br />concentrations at which the individual active substances have only a bacteriostatic effect. Bactrim<br />is also often effective against organisms that are resistant to one of the two components. Thanks to<br />the dual effect of Bactrim, the risk of widespread resistance developing is minimised.<br />The in vitro antibacterial effect of Bactrim extends to gram-positive and gram-negative pathogens<br />and includes the following organisms, although susceptibility may vary geographically:<br />Commonly susceptible organisms (MIC ˂80 mg/l)*<br />Cocci: Branhamella catarrhalis.<br />Gram-negative rods: Haemophilus parainfluenzae, Klebsiella oxytoca, other Klebsiella spp.,<br />Enterobacter aerogenes, Hafnia alvei, Serratia marcescens, Serratia liquefaciens, other Serratia<br />spp., Yersinia enterocolitica, other Yersinia spp., Vibrio cholerae.<br />Various gram-negative rods: Edwardsiella tarda, Alcaligenes faecalis, Burkholderia<br />(Pseudomonas) pseudomallei.</p><p>&nbsp;</p><p>Based on available clinical experience, the following organisms should also be considered<br />susceptible: Brucella, Listeria monocytogenes, Nocardia asteroides, Pneumocystis jirovecii,<br />Cyclospora cayetanensis.<br />Partly susceptible organisms (MIC = 80&ndash;160 mg/l)*<br />Cocci: Staphylococcus aureus (methicillin-susceptible and methicillin-resistant), Staphylococcus<br />spp. (Coagulase-negative), Streptococcus pneumoniae (penicillin-susceptible, penicillinresistant).<br />Gram-negative rods: Haemophilus influenzae (&beta;-lactamase-positive, &beta;-lactamase-negative),<br />Haemophilus ducreyi, E. coli, Klebsiella pneumonia, Proteus mirabilis, Proteus vulgaris,<br />Morganella morganii, Shigella spp., Enterobacter cloacae, Providencia rettgeri, other<br />Providencia spp., Salmonella typhi, Salmonella enteritidis, Stenotrophomonas maltophilia<br />(formerly Xanthomonas maltophilia), Citrobacter freundii, other Citrobacter spp.<br />Various gram-negative rods: Acinetobacter lwoffi, Acinetobacter anitratus (primarily<br />A. baumanii), Aeromonas hydrophila.<br />Resistant organisms (MIC &gt;160 mg/l) *<br />Burkholderia (Pseudomonas) cepacia, Pseudomonas aeruginosa, Mycoplasma spp.,<br />Mycobacterium tuberculosis, Treponema pallidum, Neisseria gonorrhoeae, Bacteroides, other<br />strictly anaerobic bacteria.<br />*SMZ equivalent<br />The local prevalence of bacterial resistance to Bactrim associated with the treated infection should<br />be known empirically when administering Bactrim.<br />In the case of infections caused by moderately susceptible organisms, it is recommended that a<br />sensitivity test be carried out to rule out any potential resistance. Susceptibility to Bactrim can be<br />determined by disk or dilution tests using standardised methods, as recommended by the European<br />Committee on Antimicrobial Susceptibility Testing (EUCAST). EUCAST recommends the<br />following susceptibility criteria:</p><p>Table 6</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Disk testa,</p><p>Inhibition zone</p><p>diameter (mm)</p></td><td colspan="2" style="vertical-align:top"><p>Dilution testb,</p><p>MIC (g/mL)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>TM</p></td><td style="vertical-align:top"><p>SMZ</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Enterobacteriaceae</p></td><td style="vertical-align:top"><p>Susceptible</p></td><td style="vertical-align:top"><p> 14</p></td><td style="vertical-align:top"><p> 2</p></td><td style="vertical-align:top"><p>&nbsp; 38</p></td></tr><tr><td style="vertical-align:top"><p>Resistant</p></td><td style="vertical-align:top"><p>&lt; 11</p></td><td style="vertical-align:top"><p>&gt; 4</p></td><td style="vertical-align:top"><p>&gt; 76</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Acinetobacter </em>spp.</p></td><td style="vertical-align:top"><p>Susceptible</p></td><td style="vertical-align:top"><p> 14</p></td><td style="vertical-align:top"><p> 2</p></td><td style="vertical-align:top"><p> 38</p></td></tr><tr><td style="vertical-align:top"><p>Resistant</p></td><td style="vertical-align:top"><p>&lt; 11</p></td><td style="vertical-align:top"><p>&gt; 4</p></td><td style="vertical-align:top"><p>&gt; 76</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Stenotrophomonas</em></p><p><em>maltophilia</em>c</p></td><td style="vertical-align:top"><p>Susceptible</p></td><td style="vertical-align:top"><p> 16</p></td><td style="vertical-align:top"><p> 4</p></td><td style="vertical-align:top"><p> 76</p></td></tr><tr><td style="vertical-align:top"><p>Resistant</p></td><td style="vertical-align:top"><p>&lt; 16</p></td><td style="vertical-align:top"><p>&gt; 4</p></td><td style="vertical-align:top"><p>&gt; 76</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Staphylococcus </em>spp.</p></td><td style="vertical-align:top"><p>Susceptible</p></td><td style="vertical-align:top"><p> 17</p></td><td style="vertical-align:top"><p> 2</p></td><td style="vertical-align:top"><p> 38</p></td></tr><tr><td style="vertical-align:top"><p>Resistant</p></td><td style="vertical-align:top"><p>&lt; 14</p></td><td style="vertical-align:top"><p>&gt; 4</p></td><td style="vertical-align:top"><p>&gt; 76</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Enterococcus </em>spp.d</p></td><td style="vertical-align:top"><p>Susceptible</p></td><td style="vertical-align:top"><p> 50</p></td><td style="vertical-align:top"><p> 0.03</p></td><td style="vertical-align:top"><p> 0.57</p></td></tr><tr><td style="vertical-align:top"><p>Resistant</p></td><td style="vertical-align:top"><p>&lt; 21</p></td><td style="vertical-align:top"><p>&gt; 1</p></td><td style="vertical-align:top"><p>&gt; 19</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Streptococcus pneumoniae</em></p></td><td style="vertical-align:top"><p>Susceptible</p></td><td style="vertical-align:top"><p> 18</p></td><td style="vertical-align:top"><p> 1</p></td><td style="vertical-align:top"><p> 19</p></td></tr><tr><td style="vertical-align:top"><p>Resistant</p></td><td style="vertical-align:top"><p>&lt; 15</p></td><td style="vertical-align:top"><p>&gt; 2</p></td><td style="vertical-align:top"><p>&gt; 38</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Streptococcus </em>groups A, B,</p><p>C and G</p></td><td style="vertical-align:top"><p>Susceptible</p></td><td style="vertical-align:top"><p>&ge; 18</p></td><td style="vertical-align:top"><p>&le; 1</p></td><td style="vertical-align:top"><p>&le; 19</p></td></tr><tr><td style="vertical-align:top"><p>Resistant</p></td><td style="vertical-align:top"><p>&lt; 15</p></td><td style="vertical-align:top"><p>&gt; 2</p></td><td style="vertical-align:top"><p>&gt; 38</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Haemophilus influenzae &amp;</em></p><p><em>Haemophilus parainfluenzae</em></p></td><td style="vertical-align:top"><p>Susceptible</p></td><td style="vertical-align:top"><p> 23</p></td><td style="vertical-align:top"><p> 0.5</p></td><td style="vertical-align:top"><p> 9.5</p></td></tr><tr><td style="vertical-align:top"><p>Resistant</p></td><td style="vertical-align:top"><p>&lt; 20</p></td><td style="vertical-align:top"><p>&gt; 1</p></td><td style="vertical-align:top"><p>&gt; 19</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Listeria monocytogenes</em></p></td><td style="vertical-align:top"><p>Susceptible</p></td><td style="vertical-align:top"><p>&ge; 29</p></td><td style="vertical-align:top"><p>&le; 0.06</p></td><td style="vertical-align:top"><p>&le; 1.14</p></td></tr><tr><td style="vertical-align:top"><p>Resistant</p></td><td style="vertical-align:top"><p>&lt; 29</p></td><td style="vertical-align:top"><p>&gt; 0.06</p></td><td style="vertical-align:top"><p>&gt; 1.14</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Pasteurella multocida</em></p></td><td style="vertical-align:top"><p>Susceptible</p></td><td style="vertical-align:top"><p>&ge; 23</p></td><td style="vertical-align:top"><p>&le; 0.25</p></td><td style="vertical-align:top"><p>&le; 4.75</p></td></tr><tr><td style="vertical-align:top"><p>Resistant</p></td><td style="vertical-align:top"><p>&lt; 23</p></td><td style="vertical-align:top"><p>&gt; 0.25</p></td><td style="vertical-align:top"><p>&gt; 4.75</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Moraxella catarrhalis</em></p></td><td style="vertical-align:top"><p>Susceptible</p></td><td style="vertical-align:top"><p>&ge; 18</p></td><td style="vertical-align:top"><p>&le; 0.5</p></td><td style="vertical-align:top"><p>&le; 9.5</p></td></tr><tr><td style="vertical-align:top"><p>Resistant</p></td><td style="vertical-align:top"><p>&lt; 15</p></td><td style="vertical-align:top"><p>&gt; 1</p></td><td style="vertical-align:top"><p>&gt; 19</p></td></tr></tbody></table><p>&nbsp;</p><p>a Disk: 1.25 &mu;g TM and 23.75 &mu;g SMZ<br />b TM and SMZ at a 1:1 ratio plus 19<br />c Breakpoints are based on high-dose therapy, &ge; 240 mg trimethoprim and 1.2 g sulfamethoxazole, administered<br />together twice daily<br />d Activity of TM and TM-SMZ against enterococci is unclear; therefore the wild-type population is classified as<br />intermediate.<br />There are no EUCAST breakpoints available for the following species with CLSI breakpoints (disk [mm]; and<br />dilution [&mu;g/mL]) given in brackets:<br />Burkholderia cepacia (S, &ge;16; I, 11&ndash;15; R, &le;10; and S, &le;2/&le;38; I, not available; R, &ge;4/&ge;76)<br />&lsquo;Other non-Enterobacteriaceae&#39;, i.e. Pseudomonas spp. and other non-fastidious, glucose-non-fermenting gramnegative<br />bacilli, but excluding P. aeruginosa, Acinetobacter spp., Burkholderia cepacia, and S. maltophilia (disk,<br />not available; and S, &ge;4/&le;38; I, not available; R, &ge;4/&ge;76)<br />Neisseria meningitidis (S, &ge;30; I, 26-29; R, &le;25; and S, &le;0.12/&le;2.4; I, 0.25/4.75; R, &ge;0.5/&ge;9.5)<br />Resistance development/Cross-resistance</p><p>&nbsp;</p><p>&nbsp;</p><p>Resistance to Bactrim rarely develops during therapy. Cross-resistance exists among all<br />sulphonamides; cross-resistance to chemically unrelated antibiotics does not occur due to acquired<br />resistance to Bactrim.<br />Synergy/Antagonism<br />There is marked synergy between sulfamethoxazole and trimethoprim. This synergy usually exists<br />even when there is resistance to one of the two components.<br />Clinical Efficacy and safety<br />The clinical efficacy of Bactrim in the most commonly approved indications (see<br />&quot;Indications/Uses&quot;) has been demonstrated in numerous clinical trials.<br />This applies in particular to prophylaxis of Pneumocystis jirovecii pneumonia (formerly known as<br />Pneumocystis carinii pneumonia, PCP) in HIV patients:<br />In a randomised study from the Netherlands with a median follow-up of one year, Bactrim Tablets<br />(80/400 mg) were compared with Bactrim forte Tablets (160/800 mg) in 260 HIV patients whose<br />CD4 cell count was below 200 cells/&mu;l and who had not previously had PCP. None of the patients<br />in the two groups contracted PCP. There were more adverse effects requiring discontinuation of<br />TM-SMZ in the group treated with Bactrim forte (hazard ratio 1.4; 95% CI 0.95&ndash;2.02).<br />In a randomised multicentre study with a median follow-up period of almost two years, daily<br />administration of Bactrim forte Tablets was compared with three-times-weekly administration of<br />Bactrim forte Tablets in 2,625 HIV patients whose CD4 cell count was below 200 cells/&mu;l and of<br />whom some had previously had PCP. In an intent-to-treat analysis, a similar annual PCP morbidity<br />rate was observed in both groups: 3.5 and 4.1 (relative risk 0.82; 95% CI 0.69&ndash;1.09). An ontreatment<br />analysis showed a lower risk of PCP when administered daily (relative risk 0.59; 95%<br />CI 0.37&ndash;0.95). Cessation of treatment with TM-SMZ due to adverse effects was more common<br />when administered daily (relative risk 2.14; 95% CI 1.73&ndash;2.66).</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TM and SMZ largely overlap in their clinically relevant pharmacokinetic properties.<br />5.2.1 Absorption<br />TM and SMZ are rapidly and almost completely absorbed in the upper gastrointestinal tract after<br />oral administration (80%&ndash;100% bioavailability). After a single administration of 160 mg TM +<br />800 mg SMZ, peak plasma concentrations of 1.5&ndash;3 mg/l for TM and 40&ndash;80 mg/l for SMZ are<br />reached in 1 to 4 hours. With repeated administration, every twelve hours, the steady-state peak<br />plasma concentrations of SMZ and TM are usually 50%&ndash;100% higher than after single oral<br />administration. Plasma levels are dose-proportional. The influence of food on the kinetics of the<br />active components of Bactrim has not been investigated. After administration of a trimethoprim<br />suspension on a full stomach, the extent of absorption is less than after administration on an empty<br />stomach, but the rate of absorption was not changed by a standard meal.<br />5.2.2. Distribution<br />The distribution volume of TM is approx. 1.6 l/kg and of SMZ approx. 0.2 l/kg. TM is 37% and<br />SMZ 62% bound to plasma proteins. As animal studies and measurements on humans have shown,<br />tissue diffusion is favorable for Bactrim. TM passes very readily and SMZ to a lesser extent from<br />the bloodstream into the interstitial fluid and other extravascular body fluids. Concentrations of<br />TM and SMZ may be elevated in inflamed tissue. TM and SMZ have been detected in the fetal<br />placenta, cord blood, amniotic fluid and foetal tissues (liver, lungs), indicating that both substances<br />cross the placental barrier. In general, foetal TM concentrations are similar to those in maternal<br />blood, but those of SMZ are lower (see section 4.6 Fertility, pregnancy and lactation &quot;). Both<br />substances are excreted into breast milk. Concentrations in breast milk are similar to (TM) or lower<br />(SMZ) than those in maternal plasma (see section 4.6 Fertility, pregnancy and lactation&quot;).<br />5.2.3 Metabolism<br />Metabolism accounts for 30% of total TM elimination. Based on the results of an in vitro study<br />conducted in human liver microsomes, the involvement of CYP3A4, CYP1A2 and CYP2C9 in the<br />oxidative metabolism of TM cannot be ruled out.</p><p>metabolites of TM are principally the 1- and 3-oxides as well as the 3&#39;- and 4&#39;-hydroxy<br />derivatives; some metabolites are active.<br />SMZ is 80% metabolised in the liver, mainly to its N4 acetyl derivative (&asymp; 40% of the administered<br />dose) and to a lesser extent by glucuronidation. SMZ is also degraded by oxidation. The first step<br />of oxidation, leading to the formation of the hydroxylamine derivative, is catalysed by CYP2C9;<br />the metabolites are inactive.<br />5.2.4. Elimination<br />In normal renal function, the half-lives of the two components are very similar (on average, ten<br />hours for TM and eleven hours for SMZ).<br />The total clearance is around 100 ml/min for TM and around 20 ml/min for SMZ.<br />The elimination half-life of TM is roughly half as long in children as in adults, while that of SMZ<br />is not significantly different.<br />Both substances and their metabolites are excreted mainly via the kidneys, both by glomerular<br />filtration and by tubular secretion. The concentration of TM in urine is roughly 100 times higher<br />than in plasma, while the concentration of SMZ is approximately five times higher.<br />Approximately two-thirds of the TM administered is excreted unchanged in urine. Depending on<br />the pH of the urine, 10&ndash;30% of a dose of SMZ is excreted unchanged in the urine.<br />The total plasma clearance of TM is equivalent to 1.9 ml/min/kg and that of SMZ to<br />0.32 ml/min/kg.<br />Renal clearance is 20&ndash;80 ml/min for trimethoprim and 1&ndash;5 ml/min for sulfamethoxazole.<br />Both substances are found in faeces to a small extent.<br />5.2.5. Pharmacokinetics in specific patient groups<br />Hepatic impairment<br />The pharmacokinetics of a single oral dose of TM-SMZ has been investigated in patients with<br />moderate (n = 4) or severe (n = 7) hepatic impairment and compared to that in healthy subjects<br />(n = 13). No significant differences in the pharmacokinetics of TM or SMZ have been found<br />between patients with renal dysfunction and healthy subjects, apart from prolongation of the<br />elimination half-life of TM by a maximum of twice the normal value in two patients with severe<br />liver damage.</p><p>Although there is no marked change in kinetics, especially for TM, in patients with hepatic<br />insufficiency, caution is nevertheless advised in patients with severe hepatic insufficiency during<br />treatment with high doses of Bactrim. For patients on haemodialysis, blood levels need to be<br />determined and dose adjustments are necessary.<br />Renal impairment<br />In patients with impaired kidney function, the elimination half-lives of both components are<br />prolonged; the dosage must be adjusted accordingly.<br />Intermittent or continuous ambulatory peritoneal dialysis has no significant effect on the<br />elimination of Bactrim. During haemodialysis and haemofiltration, considerable amounts of TM<br />and SMZ are removed. It is therefore recommended that the dose of Bactrim be increased by 50%<br />after each haemodialysis session. In children with renal insufficiency (CLcr &lt; 30 ml/min),<br />clearance of TM is reduced and its elimination half-life prolonged. The TM-SMZ dosage in<br />paediatric patients with impaired renal function should be adjusted based on renal function (see<br />section 4.2 &quot;Psology and method of administration, Patients with renal dysfunction&quot;).<br />Elderly patients<br />Owing to the importance of renal clearance in the TM elimination process and due to the fact that<br />creatinine clearance decreases physiologically with increasing age, a decrease in the renal<br />clearance and total body clearance of TM can be expected with age. The pharmacokinetics of SMZ<br />should be less affected by increasing age, as renal clearance of SMZ accounts for only 20% of<br />total SMZ clearance.<br />The dosage must be adjusted accordingly.<br />Children and adolescents<br />The results of various clinical pharmacokinetic studies conducted in the paediatric patient group<br />with normal renal function have confirmed that the pharmacokinetics of both Bactrim components,<br />TM and SMZ, is age-dependent in this patient group. Whilst elimination of TM-SMZ is reduced<br />in neonates in the first two months of life, TM and SMZ are eliminated more rapidly thereafter,<br />with greater total body clearance and a shorter elimination half-life. The differences are most<br />marked in infants (&gt; 1.7 months to 24 months) and decrease with increasing age, compared to<br />toddlers (1 year to 3.6 years), children (7.5 years to &lt; 10 years) and adults (see section 4.2<br />&quot;Posology and method of administration &quot;).</p><p>patients with mucoviscidosis<br />Renal clearance of TM and metabolic clearance of SMZ are increased in mucoviscidosis patients.<br />Hence, the total plasma clearance is increased and the elimination half-life decreased for both<br />active substances.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TM also inhibits folic acid reductase in mammalian cells, but many orders of magnitude higher<br />concentrations are required than in bacteria. Several studies have revealed that high doses of a<br />combination of TM and sulphonamides cause malformations and embryonic lethality in rats. Folic<br />acid antagonism appears to exist under these experimental conditions. However, the doses used<br />were 10 - 100 times higher than the therapeutic doses used in humans. TM is mutagenic in vitro.<br />SMZ produces thyroid carcinomas in rats. This finding appears to be species-specific and is<br />probably not clinically significant for humans.<br />Other information<br />Effects on diagnostic methods<br />Bactrim, in particular its component TM, may interfere with competitive protein binding assays<br />for methotrexate if bacterial dihydrofolate reductase is used as a binding protein. No interaction<br />occurs, however, when methotrexate is determined by radioimmunoassay. TM and SMZ can also<br />interfere with the Jaff&eacute; test (alkaline picrate acid reaction assay for creatinine), resulting in<br />overestimations of about 10% in the range of normal values.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bactrim forte, Tablets<br />Dioctyl Sodium Sulfosuccinate<br />Magnesium Stearate<br />Sodium Starch Glycolate<br />Povidone 30</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use this medicine after the expiry date ("EXP") stated on the container.
Bactrim Forte tablets: 36 months (3 years).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bactrim forte, Tablets:<br />Do not store above 25&deg;C.<br />Keep out of the reach and sight of children</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bactrim Forte tablets 160 mg TM and 800 mg SMZ.<br />A white to almost white, oblong, biconvex tablet with one side plain and the other side with a<br />breakline tablet.<br />Each unit carton contains 10 tablets in 1 blister strip.<br />Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EUMEDICA Pharmaceuticals AG,
Arnold Böcklin-Strasse 1,
4051 Basel, Switzerland.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>